Cell cycle exit during bortezomib‐induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s‐upregulated p21(Cip1) and p27(Kip1)

Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiating into a variety of cell types. Bortezomib, the first approved proteasome inhibitor used for the treatment of multiple myeloma (MM), has been shown to induce osteoblast differentiation, making it beneficial for myeloma bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dan, Fan, Rong, Lei, Li, Lei, Lei, Wang, Yanmeng, Lv, Nan, Chen, Ping, Williamson, Ramone A., Wang, Baiyan, Hu, Jinsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417721/
https://www.ncbi.nlm.nih.gov/pubmed/32628811
http://dx.doi.org/10.1111/jcmm.15605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417721/
https://www.ncbi.nlm.nih.gov/pubmed/32628811
http://dx.doi.org/10.1111/jcmm.15605

Ejemplares similares